Maternal serum lactate dehydrogenase level as a predictor of adverse pregnancy outcome in women with severe preeclampsia
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20240110Keywords:
Adverse pregnancy outcome, LDH, Severe preeclampsiaAbstract
Background: Preeclampsia is a multisystem disorder causing vascular endothelial damage and leads to leakage of lactate dehydrogenase (LDH) into maternal serum. This study evaluated the serum LDH levels in severe preeclamptic women to detect any correlation with adverse pregnancy outcomes.
Methods: A prospective cohort study compared LDH levels of 68 severe preeclamptic women with 68 normotensives in the third trimester, matched for age, parity, and gestational age. The preeclamptic women were followed up until delivery to assess the maternal and neonatal outcomes. Data were analyzed with SPSS for Windows version 23. The level of significance was set at p<0.05.
Results: Both groups were comparable in their characteristics. The mean LDH level for severe preeclamptic group (717.40 IU/L) was higher than for the normotensive group (162.90 IU/L) and this was significant (p=0.001). Cesarean delivery was less likely when LDH was >600 compared to ≤600 (OR 0.31; p=0.049) indicating a potential protective effect. The likelihood of IUGR (OR 3.14; p=0.045), IUFD (OR 6.48; p=0.028), stillbirth (OR 7.06 p=0.007), perinatal mortality (OR 4.84; p=0.004) and low birth weight <2500 gm (OR 3.77; p=0.025) were all significantly higher with LDH levels >600 IU/L.
Conclusions: Maternal serum LDH levels were found to be significantly increased in pregnant women with severe preeclampsia compared to their normotensive counterparts, and elevated levels >600 IU/L in the third trimester was associated with adverse perinatal outcomes.
Metrics
References
Mol BWJ, Roberts CT, Thangaratinam S, Magee LA, de Groot CJM, Hofmeyr GJ. Pre-eclampsia. The Lancet 2016;387(10022):999-1011.
NA. Hypertension in pregnancy. Obstetr Gynecol. 2013;122(5):1122-31.
Tranquilli AL, Dekker G, Magee L, Roberts J, Sibai BM, Steyn W et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from ISSHP. Pregnancy Hypertens. 2014;4(2):97-104.
Brown MA, Magee LA, Kenny LC, Karumanci SA, McCarthy FP, Saito S et al. The hypertensive disorders of pregnancy: ISSHP classification, diagnosis and management recommendations for international practice. Pregnancy Hypertens. 2018;13:291-310.
Norwitz ER, Hsu CD, Repke JT. Acute complications of preeclampsia. Clin Obstet Gynecol. 2002;45(2):308-29.
Dutta DC. Hypertensive disorders in pregnancy. In: Konar H, editor. Textbook of Obstetrics. 6th Ed. Ch. 17. Calcutta: New central book agency. 2001;1:221-42.
Sibai B. Evaluation and management of severe preeclampsia before 34 weeks’ gestation. Am J Obstetr Gynecol. 2011;205(3):191-8.
Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol. 1989;161:1200-4.
Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA. Pathophysiology of preeclampsia: linking placental ischemia/hypoxia with microvascular dysfunction. Microcirculation. 2002;9(3):147-60.
Krefetz RG. Enzymes. Clinical Chemistry, 4th Ed. Lippincott Williams and Wikins; Philadelphia. 2000;196-98.
Clinical Enzymology and Biomarkers. In: Vasudevan D, Sreekumari S. (ed). Textbook of Biochemistry. 6th Edition, Jaypee Brothers, New Delhi. 2011;146-59.
Butt AA, Michaels S, Greer D, Clark R, Kissinger P, Martin DH. Serum lactate dehydrogenase level as a clue to the diagnosis of histoplasmosis. AIDS Read. 2002;12(7):317-21.
Makuyana D, Mohamed K, Shukusho FD, Majoko F. Liver and kidney function tests in normal and preeclamptic women: a comparison with non-gestational reference values. Centr Afr J Med. 2002;48:55-9.
Madazli R, Aydin S, Uludag S, Vildan O, Tolun N. Maternal plasma levels of cytokines in normal and preeclamptic pregnancies and their relationship with diastolic blood pressure and fibronectin levels. Acta Obstet Gynecol Scand. 2003;82:797-802.
Belo L, Santos-Saliva A, Rumley A, Lowe G, Pereira-Leite L, Quintanilha A et al. Elevated tissue plasminogen activators as a potential marker of endothelial dysfunction in pre-eclampsia: correlation with proteinuria. BJOG. 2002;109(11):1250-55.
Cekmen MB, Erbagci AB, Balat A, Dunman C, Maral H, Ergen K et al. Plasma lipid and lipoprotein concentration in pregnancy induced hypertension. Clin Biochem. 2003;36(7):575-8.
Peralta Pedrero ML, Basavilvazo Rodriguez MA, Cruz Avelar A, Sanchez Ambriz S, Guzman Ibarra ML, Martinez Garcia MC. Clinical significance of the laboratory determinations in preeclamptic patients. Ginecol Obstet Mex. 2004;72:57-62.
Malarewicz A, Gruszka O, Szymkiewicz J, Rogale J. The usefulness of routine laboratory tests in the evaluation of sudden threat of pregnant women and fetus in pre-eclampsia. Ginecol Pol. 2006;77(4):276-84.
Rubina Aziz, Tabassum Mahboob. Association between pre-eclampsia and serum lactate dehydrogenase and aspartate transaminase levels. ARYA Atherosclerosis J. 2008;4(1):29-32.
Kiren K, Malik, Noreen Akmal, Naseem Akhter. Correlation of lactate dehydrogenase levels with the severity of pre-eclampsia. Tohoku J Exp Med. 2004;202(7):87-92.
Munde SM, Hazari NR, Thorat AP, Gaikwad SB, Hatolkar VS. Gamma-glutamyl transferase and Lactate dehydrogenase as biochemical markers of severity of preeclampsia. Int J Med Health Pharm Biomed Eng. 2014; 8(1): 50-3.
Sarkar PD, Sogani S. Evaluation of serum lactate dehydrogenase and gamma glutamyl transferase in preeclamptic pregnancy and its comparison with normal pregnancy in third trimester. Int J Res Med Sci. 2013;1(4):365-8.
Qublan HS, Ammarin VC, Bataineh O, Al-Shraideh Z, That Y, Awamleh I et al. Lactic dehydrogenase as a biochemical marker of adverse pregnancy outcome in severe pre-eclampsia. Med Sci Monit. 2005;11(8):393-7.
Jaiswar SP, Amrit G, Rekha S, Natu SN, Mohan S. Lactic dehydrogenase: A biochemical marker for preeclampsia-eclampsia. J Obstet Gynaecol India. 2011;61(6):645-8.
Bera S, Gupta S, Roy SS, Kunti S, Biswas S, Ghosh D. Study of liver enzymes especially lactate dehydrogenase to predict foetal outcome in pregnancy induced hypertension. Sch J App Med Sci. 2014;2(5):1569-72.
Gruccio S, Di Carlo MB, Pandolfo M, Cruza GS, Touzona MS, Negria G et al. Biochemical profiling study in umbilical cord blood as predictors of neonatal damage. Int J Clin Pediatr. 2014;3(1):5-11.
Kotrlik J, Higgins C. Barlett J.E. Organizational research: Determining appropriate sample size in survey research appropriate sample size in survey research. Info Technol Learning Performance J. 2001;19(1):1-8.
Andrews L, Patel N. Correlation of serum lactate dehydrogenase and pregnancy induced hypertension with its adverse outcomes. Int J Res Med Sci. 2016;4(5):1347-50.
Magann EF, Martin JN. Twelve steps to optimal management of HELLP syndrome. Clin Obstet Gynecol 1999;42(3):532-50.
Bhati BS, Mirza N, Choudhary PK. Correlation of lactate dehydrogenase levels with outcome in patients with pre-eclampsia. Adv Hum Biol. 2020;10:149-52.
Deshmukh VL, Kollur A, Gadappa SN. A correlation of lactate dehydrogenase (LDH) enzyme levels in hypertensive disorders of pregnancy with severity of disease, maternal and perinatal outcome. N Indian J OBGYN. 2020;7(1):20-5.
Kharb S, Bhandari N, Singh A, Gupta A. Lactate dehydrogenase and maternal and perinatal outcome in preeclamptic women. Arch Med Health Sci. 2019;7:163-6.
Dave A, Maru L, Jain A. LDH (lactate Dehydrogenase): A Biochemical Marker for the prediction of Adverse Outcomes in Pre-eclampsia and Eclampsia. J Obstet Gynaecol India. 2016;66(1):23-9.
Moharana JJ, Mishra R, Nayak AK. A study on serum lactate dehydrogenase and uric acid in preeclampsia and eclampsia: Can they predict adverse fetomaternal outcome? Int J App Basic Med Res. 2023;13:95-100.
Jharia J, Mathur P, Dave A, Mathur P. A prospective study to assess role of serum lactate dehydrogenase in prediction of adverse outcomes of pre-eclampsia and eclampsia. Int J Reprod Contracep Obstet Gynecol 2016;5:2522-9.